Ascendis Pharma (ASND) Misses Q4 EPS by 775c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR10.40), EUR7.75 worse than the analyst estimate of (EUR2.65). Revenue for the quarter came in at EUR51.17 million versus the consensus estimate of EUR19.55 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Is the global equity rally broadening? UBS weighs in